TScan Therapeutics

TScan Therapeutics EBITDA per Employee

The EBITDA per Employee of TScan Therapeutics (TCRX) as of Oct 30, 2026 is -936,641.38 USD. In the previous year, EBITDA per Employee was -929,800.00 USD — a change of 0.74% (lower).

EBITDA per Employee

-936,641.38USD

YoY

0.74%

Last updated:

EBITDA per Employee of TScan Therapeutics is 2025 -936,641.38 USD. EBITDA per Employee of TScan Therapeutics was 2024 -929,800.00 USD. It decreases by 0.74% lower compared to the previous year.

The TScan Therapeutics EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2019
-98,000.00 USD
Jan 1, 2020
-180,917.24 USD
Jan 1, 2021
-335,455.17 USD
Jan 1, 2022
-459,558.62 USD
Jan 1, 2023
-644,537.93 USD
Jan 1, 2024
-929,800.00 USD
Jan 1, 2025
-936,641.38 USD
The TScan Therapeutics EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-936,641.38USD+0.74%
-929,800.00USD+44.26%
-644,537.93USD+40.25%
-459,558.62USD+37.00%
-335,455.17USD+85.42%
-180,917.24USD+84.61%
-98,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TScan Therapeutics Stock analysis

What does TScan Therapeutics do? TScan Therapeutics, Inc. develops TCR-T therapies for liquid cancers and solid tumors, focusing on TSC-100 and TSC-101 for hematologic malignancies post-transplant. The company builds its ImmunoBank with solid tumor targets across HLA types and advances six solid tumor programs including TSC-204 in Phase I and TSC-200/TSC-203 in IND-enabling activities. TScan generates revenue through clinical development partnerships and future product sales of its TCR-T therapies. Its primary customers are healthcare providers and patients seeking advanced cancer treatments. The company targets the oncology segment with a focus on hematologic malignancies and solid tumors, leveraging its ImmunoBank to expand therapeutic options. TScan Therapeutics, Inc. is developing TCR-T therapies for cancer treatment, with lead candidates TSC-100 and TSC-101 in clinical development for hematologic malignancies. The firm’s ImmunoBank collects solid tumor targets across HLA types to support multiplexed TCR-T therapies. TScan advances six solid tumor programs, including TSC-204 entering Phase I and TSC-200/TSC-203 in IND-enabling stages. Revenue comes from partnerships with biopharmaceutical companies for clinical development and eventual sales of TCR-T therapies. The target market includes oncology specialists and cancer patients requiring novel treatments for residual disease and relapse prevention. The company’s pipeline includes TSC-100 and TSC-101 for hematologic malignancies after transplantation and TSC-204 to TSC-205 for solid tumors. TScan’s ImmunoBank enables multiplexed TCR-T therapies targeting various solid tumors. Revenue streams are derived from clinical development collaborations and future commercialization of its therapies. Key segments are oncology providers treating hematologic malignancies and solid tumors, with a focus on post-transplant residual disease management and relapse prevention. TScan Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TScan Therapeutics stock

EBITDA per Employee of TScan Therapeutics is -936,641.38 USD in 2025.

EBITDA per Employee of TScan Therapeutics changed from -929,800.00 USD to -936,641.38 USD, representing a 0.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee TScan Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's TScan Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — TScan Therapeutics

All Key Metrics — TScan Therapeutics